Welcome to our dedicated page for Lifeward news (Ticker: LFWD), a resource for investors and traders seeking the latest updates and insights on Lifeward stock.
Lifeward Ltd. (Nasdaq: LFWD) is a medical device company that focuses on technologies for physical rehabilitation and recovery, including the ReWalk Exoskeleton, ReWalk 7 Personal Exoskeleton, ReStore Exo-Suit, MyoCycle FES System, and AlterG Anti-Gravity System. This news page aggregates company press releases and third-party coverage so readers can follow how Lifeward’s business and strategy develop over time.
Recent news highlights Lifeward’s progress in reimbursement and market access for its ReWalk 7 Personal Exoskeleton. The company has reported prior authorization approvals and payments from Medicare Advantage plans, including UnitedHealthcare and a Humana Medicare Advantage Plan, following the establishment of a formal Medicare reimbursement pathway for personal exoskeletons by CMS. These updates provide insight into payer adoption trends and Lifeward’s efforts to support access for individuals with spinal cord injury.
Lifeward’s news flow also covers international expansion and regulatory milestones. The company announced CE mark approval for the ReWalk 7 Personal Exoskeleton, enabling commercial sales in Europe, and a distribution agreement with Verita Neuro to offer ReWalk in Mexico, Thailand, and the United Arab Emirates. These items help investors and clinicians understand how Lifeward is extending its commercial footprint beyond its core markets in the United States, Israel, and Germany.
Another important theme in Lifeward’s news is its strategic partnership with Oramed Pharmaceuticals. The parties have agreed to transfer Oramed’s Protein Oral Delivery (POD™) technology to Lifeward, with Oramed becoming a significant shareholder and managing the clinical program. Coverage of this transaction explains how Lifeward aims to operate as a biomedical portfolio company that combines revenue-generating MedTech products with longer-term biotech opportunities.
Visitors can use this page to review updates on financial results, capital raises, board and management changes, regulatory approvals, reimbursement developments, and strategic transactions involving LFWD.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.